{"summary": "CCZ is a first-generation antihistamine of the phenylpiperazine class. it is approved to alleviate allergy symptoms such as rhinitis, urticaria, and pruritus. it has several disadvantages: first, it has to be taken multiple times during the day due to the short half-life. the current SVR rates for chronic hepatitis C patients with FDA approved therapy are between 90\u201395% (8). it is nearly impossible to demonstrate clinically that addition of a newer agent can result in improved efficacy or SVR."}